The management of menopausal sequelae in patients with breast cancer

Clinical Oncology

Volumn 13, Issue 3, 2001, Pages 174-180

  Rostom, A Y ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Menopause; Treatment of symptoms

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; MEGESTROL ACETATE; TAMOXIFEN; VENLAFAXINE;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DEPRESSION; EARLY MENOPAUSE; EXERCISE; FEMALE; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; MEDICAL DECISION MAKING; MENOPAUSE; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY; VASOMOTOR REFLEX; WEIGHT BEARING;

EID: 0034955784     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.9249     Document Type: Article

References (56)

1. Peto R, Boreham J, Clark M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69. Lancet 2000;355:1822.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-41.
3. Zujewski J, Liu ET. The 1998 St Gallen consensus conference: an assessment. J Natl Cancer Inst 1998;90:1587-9.
4. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998;90:1601-8.
5. Powles TJ. Prognostic impact of amenorrhea after adjuvant chemotherapy. Eur J Cancer 1998;34:603-5.
6. Jordan VC. Chemotherapy is antihormonal therapy - how much proof do oncologists need?. Eur J Cancer 1998;34:606-8.
7. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70.
8. Castiglione-Gertsch M, Gelber RD, O'Neill A, et al. Systemic adjuvant treatment for premenopausal node-negative breast cancer. Eur J Cancer 2000;36:549-50.
9. Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women's health related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14.
10. Trichopolous D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:606-13.
11. Toniolo PG, Levittz M, Zeleniuch-Jaquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
12. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome. J Clin Oncol 1999;17:1482-7.
13. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flushes with transdermal clonidine. Am J Obstet Gynecol 1987;156:561-5.
14. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flushes in breast cancer survivors. J Clin Oncol 1998;16:495-500.
15. Loprinzi CL, Michalak JC, Quella SK, et al. Megastrol acetate for the treatment of hot flushes. N Engl J Med 1994;331:347-52.
16. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megastrol acetate by cancer survivors for the treatment of hot flushes. Cancer 1998;82:1784-8.
17. Loprizi CL, Kugler JW, Sloan J, et al. Venlafaxine alleviates hot flashes [abstract]. Proc ASCO 2000;18:A4.
18. Duffy LS, Greenberg DB, Younger J, et al. Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics 1999;40:304-8.
19. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital deficiency: a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-7.
20. Nachtigall LE. Comparative study of Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
21. Raz R, Stamm WE. A controlled trial of intravaginal estriol in post menopausal women with recurrent urinary tract infection. N Engl J Med 1993;329:753-6.
22. Cuzick J, Stewart H, Rutqvist L, et al. Cause specific mortality in long term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994;12:447-53.
23. Nixon AJ, Manola J, Gelman R, et al. No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation using modern techniques. J Clin Oncol 1998;16:1374-9.
24. Ibrahim NK, Hortobagyi GN, Ewer M, et al. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long term follow-up: the MD Anderson experience. Cancer Chemother Pharmacol 1999;43:471-8.
25. Valgussa P, Zambetti M, Biasi S, et al. Cardiac effects following adjuvant chemotherapy and breast radiotherapy in operable breast cancer. Ann Oncol 1994;5:209-16.
26. Findlay I, Cunningham D, Dargie H. Coronary heart disease, the menopause and hormone replacement therapy [editorial]. Br Heart J 1994;71:213-4.
27. Stampfer MJ, Colditz GA. Oestrogen therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:20-47.
28. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991;303:435-7.
29. Love RR, Mamby CC, Feyzi JM. Tamoxifen-induced decreases in total cholesterol with 2 weeks of treatment. J Natl Cancer Inst 1993;85:1344-5.
30. Pouilles JM, Tremolieres F, Bonneu M, et al. Effect of early age at menopause on vertebral bone mass. J Bone Miner Res 1994;9:311-5.
31. Shapiro CL, Neuberg D, Scholnidk J, et al. Chemotherapy-induced ovarian failure is associated with significant bone loss in early stage breast cancer patients [abstract]. Proc ASCO 1997;16:A500.
32. Headley JA, Theriault RL, LeBlanc AD, et al. Pilot study of bone mineral density in patients treated with adjuvant chemotherapy. Cancer Invest 1998;16:6-11.
33. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy-X-ray absorbimetry on healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
34. Osborn CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
35. Resch A, Biber E, Seifert M, et al. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol 1998;37:661-4.
36. National Osteoporosis Foundation clinical practice guidelines. Physician's guide to the prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 1999.
37. Pols HAO, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled randomized trial of the effect of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis Int 1999;9:461-8.
38. Cummings SR, Blake DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998; 280:2077-82.
39. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998;70:704-8.
40. Mijatovic V, van der Mooren MJ, Kenmans P, et al. Raloxifene lowers serum lipoprotein (A) in healthy postmenopausal women: a randomised, double-blind, placebo-controlled comparison with conjugated equine estrogen. Menopause 1999;6:134-7.
41. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial. JAMA 1999;281:2189-97.
42. Burstein JH, Gelber S, Guadagnoli E, et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1758-9.
43. Glanville M. Natural alternative to HRT. London: Kyle and Cathie, 1997.
44. Chenoy R, Hussain S, Tayob Y, et al. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 1994;308:501-3.
45. Szarewski A. Keep taking the tablets for HRT. Lancet 1997;350:37.
46. Ganz P. Hormone replacement therapy and breast cancer. Oncology 1999;13:257.
47. Brzezinski A, Debi A. Phytoestrogens: the 'natural' selective estrogen receptor modulators? Eur J Obstet Gynaecol Reprod Biol 1999;85:47-51.
48. Eden J. Phytoestrogen and the menopause. Baillieres Clin Endocrinol Metab 1998;12:581-7.
49. Anderson J, Johnston B, Cook-Newell M. Meta analysis of the effect of soy proteins intake on serum lipid. N Engl J Med 1995;333:276-82.
50. Murkias AL, Wilcox G, Davies SR. Phytoestrogens. J Clin Endocrinol Metab 1998;83:297-303.
51. Quella SK, Loprinizi CL, Barton JA, et al. Evaluation of soy phytoestrogen for the treatment of hot flushes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 2000;18:1068-74.
52. Mulrow CD, Williams JW, Trivedi M, et al. Treatment of depression - newer pharmacotherapies. Psychopharmacol Bull 1998;34:409-795.
53. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: a randomised multicentre study of treatment for eight weeks. BMJ 1999;319:1534-8.
54. Fugh-Berman A. Herbdrug interactions. Lancet 2000; 355:134-8.
55. Ganz PA, Greendale GA, Khan B, et al. Are older breast carcinoma survivors willing to take hormone replacement therapy? Cancer 1999;86:814-20.
56. Motluk A. Hope on ice: reversing the menopause may be tougher than we think. New Sci 1999;164(2206):5.